MASI - Masimo Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
138.16
-2.42 (-1.72%)
As of 11:08AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close140.58
Open139.47
Bid138.18 x 1400
Ask138.40 x 1000
Day's Range137.39 - 139.50
52 Week Range96.14 - 147.91
Volume68,013
Avg. Volume471,282
Market Cap7.372B
Beta (3Y Monthly)1.32
PE Ratio (TTM)39.49
EPS (TTM)3.50
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-11-23
1y Target Est155.20
Trade prices are not sourced from all markets
  • Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises
    Zacks1 hour ago

    Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises

    Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.

  • Here's Why You Should Hold On to Integra LifeSciences Stock
    Zacks2 hours ago

    Here's Why You Should Hold On to Integra LifeSciences Stock

    Investor confidence is still high on growth prospects of Integra LifeSciences (IART).

  • QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
    Zacks3 hours ago

    QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access

    This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.

  • Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
    Zacksyesterday

    Hologic Breast Health Arm Aids Strongly, Rising Costs Ail

    Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.

  • Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?
    Zacksyesterday

    Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?

    Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.

  • ResMed Study Shows Remote Monitoring Benefits on CPAP Use
    Zacksyesterday

    ResMed Study Shows Remote Monitoring Benefits on CPAP Use

    Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.

  • Here's Why You Should Buy Masimo (MASI) Stock Right Now
    Zacksyesterday

    Here's Why You Should Buy Masimo (MASI) Stock Right Now

    Masimo (MASI) benefits from launches like Halo ION.

  • Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
    Zacks2 days ago

    Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring

    Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Masimo Corp.

    Masimo Corp NASDAQ/NGS:MASIView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for MASI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MASI. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.22 billion over the last one-month into ETFs that hold MASI are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects
    Zacks2 days ago

    Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects

    Avedro (AVDR) gains from promising developments in recent times.

  • Varian Medical's CTSI Buyout to Boost Oncology Services Unit
    Zacks2 days ago

    Varian Medical's CTSI Buyout to Boost Oncology Services Unit

    The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.

  • Why Should You Hold on to Myriad Genetics (MYGN) Stock?
    Zacks2 days ago

    Why Should You Hold on to Myriad Genetics (MYGN) Stock?

    Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

  • LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses
    Zacks3 days ago

    LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses

    LabCorp's (LH) diagnostics business grows organically despite additional price reductions.

  • 7 A-Rated Healthcare Stocks for Industry Expansion
    InvestorPlace3 days ago

    7 A-Rated Healthcare Stocks for Industry Expansion

    According to the Centers for Medicare and Medicaid Services, healthcare spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP; a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 High-Yield REITs to Buy (Even When the Market Tanks) That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets.Source: Flickr Masimo (MASI)Masimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 44% in the past 12 months, and much of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on. * 6 Chinese Stocks That Could Pop On a Trade Deal This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments.IONS is already partnered with a number of larger pharmaceutical firms and is up 55% in the past year, with plenty of headroom left.Source: Shutterstock Osiris Therapeutics (OSIR)Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 141% for the year and 40% in 2019.Source: Shutterstock Ensign Group (ENSG)Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles. * 10 Retirement Stocks That Won't Wilt in a Bear Market It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is.Up 59% in the past year, its size makes it a potential takeover target or a big grower on its own.Source: Shutterstock Genomic Health (GHDX)Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 38% in the past year and it's still going strong.Source: Shutterstock National Research Corp (NRC)National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research. * 7 Cloud Stocks to Buy on Overcast Days While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain.Up 26% in the past year, NRC also delivers a nearly a 2% dividend.Source: Shutterstock AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Although its global potential looks huge as China looks to upgrade its entire healthcare system, it's been volatile over the last year and relatively flat (actually down .3%). Most of the volatility is trade war related and that can't last forever.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.

  • Medtronic (MDT) Launches Telescope Guide Extension Catheter
    Zacks3 days ago

    Medtronic (MDT) Launches Telescope Guide Extension Catheter

    The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.

  • ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI
    Zacks3 days ago

    ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

    ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

  • New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery
    Business Wire3 days ago

    New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery

    Masimo  announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of

  • QIAGEN Partners Inovio to Develop Companion Diagnostics
    Zacks6 days ago

    QIAGEN Partners Inovio to Develop Companion Diagnostics

    QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

  • Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site
    Zacks6 days ago

    Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site

    The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.

  • Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
    Zacks6 days ago

    Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

    Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...

  • Varian Medical Installs ProBeam at Research Hub in Singapore
    Zacks6 days ago

    Varian Medical Installs ProBeam at Research Hub in Singapore

    Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.

  • Is Masimo Corporation's (NASDAQ:MASI) ROE Of 20% Impressive?
    Simply Wall St.7 days ago

    Is Masimo Corporation's (NASDAQ:MASI) ROE Of 20% Impressive?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Business Wire7 days ago

    Masimo Hosts 2019 Investor Day

    Masimo is hosting an Investor Day at its headquarters in Irvine today, which will include presentations by Chairman and Chief Executive Officer Joe Kiani and other members of the executive team.

  • Masimo Announces FDA Clearance of Radius PPG™, the First Tetherless SET® Pulse Oximetry Sensor Solution
    Business Wire7 days ago

    Masimo Announces FDA Clearance of Radius PPG™, the First Tetherless SET® Pulse Oximetry Sensor Solution

    Masimo  announced today FDA 510 clearance of Radius PPG, a tetherless sensor solution powered by Masimo SET® that represents a significant breakthrough in patient monitoring.